IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12023332 B1

PDFFull Text
Date of Patent:
Jul. 02, 2024

Filed:

Mar. 05, 2019

Compositions and methods for activating signaling through the cb1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin

Applicant:

Wylder Nation Foundation, Scottsdale, AZ (US);

Inventors:

Maria Dolores Ledesma, Scottsdale, AZ (US);

Adrian Bartoll, Scottsdale, AZ (US);

Edward H. Schuchman, Scottsdale, AZ (US);

Assignee:

Wylder Nation Foundation, Scottsdale, AZ (US);

Attorney:

COOLEY LLP

Primary Examiner:

Golam M Shameem

Int. Cl.
CPC ...
A61K 31/501 (2006.01); A61K 9/00 (2006.01); A61K 31/16 (2006.01); A61K 31/164 (2006.01); A61K 31/232 (2006.01); A61K 31/325 (2006.01); A61K 31/415 (2006.01); A61K 31/4164 (2006.01); A61K 31/4545 (2006.01); A61K 31/496 (2006.01); A61K 31/573 (2006.01); A61K 35/28 (2015.01); A61K 45/06 (2006.01); A61P 1/00 (2006.01); A61P 25/28 (2006.01); C12N 9/16 (2006.01);
U.S. Cl.
CPC ...
A61K 31/501 (2013.01); A61K 9/0085 (2013.01); A61K 31/16 (2013.01); A61K 31/164 (2013.01); A61K 31/232 (2013.01); A61K 31/325 (2013.01); A61K 31/415 (2013.01); A61K 31/4164 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/573 (2013.01); A61K 35/28 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2018.01); A61P 25/28 (2018.01); C12N 9/16 (2013.01); C12Y 301/04012 (2013.01);
Abstract

The present invention provides, inter alia, compositions and methods for using CB1 cannabinoid receptor agonists, or other compounds capable of increasing endocannabinoids or endocannabinoid signaling, for treating and preventing lysosomal storage disorders in which lipid storage occurs (including, e.g., disorders associated with sphingomyelin accumulation). In particular embodiments, the present invention provides compositions and methods for treating such lysosomal storage disorders with one or more fatty acid amide hydrolase inhibitor alone or in combination with one or more additional agent.

Find Patent Forward Citations

Loading…